antiviral news
Press Releases in the global landscape
Jul 8, 2026
Paxlovid safe for children age 6 and up, new data reveal
A study finds that the antiviral drug is safe to prescribe in children with COVID-19 who are at least 6 years old.
Read More »
Jun 30, 2026
Newly Approved Xocova Cuts SARS-CoV-2 Transmission To Household Contacts
An antiviral drug approved in Japan to treat COVID-19 can be effective post-exposure prophylaxis, too.
Read More »
Jun 26, 2026
Pfizer Trial Backs Paxlovid Dose for High-Risk Children
A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID. Medscape Medical News
Read More »
Jun 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
Pfizer’s oral COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) and Novo Nordisk Pharma’s once-weekly basal insulin Awiqli (insulin icodec) are set for NHI price reductions in Japan under the cost-effectiveness assessment (CEA) scheme.
Read More »
Jun 25, 2026
HKUMed–Tsinghua team develops first-in-class broad-spectrum small-molecule antiviral to combat SARS-CoV-2 and related coronaviruses
HKUMed–Tsinghua team develops first-in-class broad-spectrum small-molecule antiviral to combat SARS-CoV-2 and related coronaviruses
Read More »
Jun 19, 2026
Shionogi Announces Supplemental Approval in Japan for Pediatric Dosage and Administration of XOCOVA® to Treat COVID-19
Approval based on Phase 3 trial in 117 children showing a 5‑day once‑daily regimen is safe with pediatric PK similar to adults, supporting weight‑based dosing. The approval expands XOCOVA to include pediatric patients 6 years and older who weigh at least 20 kg and introduces 25 mg tablets. Impact on the company’s fiscal year 2027 results is expected to be minimal.
Read More »